Meet with… Novo Ventures
Johnson & Johnson Innovation, JLABS , 329 Oyster Point Blvd , South San Francisco , CA
October 03, 2017 from 12:30 PM to 15:00 PM (PDT)
$10 - $35
Do you want to meet with one of the most active Life Science investors in the World? Novo Ventures is the venture investment vehicle for Novo A/S – a holding and investment company that manages ~$45B of assets on behalf of the Novo Nordisk Foundation.
*Companies must have applied for a one-on-one meeting ahead of time and been approved. Applications are due September 6th. Apply Here.
Novo Ventures is structured as an evergreen fund with an annual total of $350M to invest in private and public life science companies in North America and Europe. Their team identifies opportunities by leveraging a local presence in leading global biotech hubs and typically co-invests with other life sciences funds as either a lead or co-lead investor.
Novo Ventures has a strong focus on pre-commercial therapeutics and commercial med-tech companies, with opportunistic investments in diagnostics and research tools. Their team of professionals in Boston, Copenhagen, London and San Francisco has an active portfolio of more than 50 companies and has invested in more than 140 companies since 2000.
For more information on Novo Ventures visit http://www.novo.dk/ventures/about
Peter Moldt, Ph.D., Partner and Kenneth Harrison, Ph.D., Senior Associate with Novo Ventures, will be in attendance to provide an overview presentation on Novo Ventures' key areas of interest and venture investment philosophy. Novo Ventures will also be meeting 1-on-1 with select companies.
Peter Moldt, PhD | Partner, Novo Venturesread bio»
Kenneth Harrison, PhD | Senior Associate, Novo Venturesread bio»
10:30AM | Registration and Networking
11:00 AM | Presentation and Q&A
11:45 AM | Networking Lunch
1:00-5:00 PM | One-on-One Meeting*
*Companies must have applied for a one-on-one meeting ahead of time and been approved. Applications are due September 6th.Apply Here.
$25 | General Public
$35 | Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until noon on October 2 (or sold out).
FREE | Application
FREE | Accepted Companies
Apply to meet one-on-one with representatives from Novo Ventures Your application will be reviewed and you will be notified of acceptance on September 19th, 2017. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved.
Peter Moldt, Ph.D. | Partner, Novo Ventures
Peter joined Novo Ventures in San Francisco, California in 2012. He is Chairman of the Board of Directors of Allakos and a member of the Board of Directors of Corvus Pharmaceuticals, Bolt Therapeutics, E-Scape Bio, Spruce Biosciences and Tioma Therapeutics. Previously, he was a board member of Cytochroma, HemoFocus, Neurokey and Orphazyme.
In 2004, Peter co-founded Curalogic A/S, served as CEO until 2009 and took the company public in 2006. From 2000-2004, he was Chief Operating Officer of 7TM Pharma A/S, which he also co-founded. Previously, he worked for 11 years with NeuroSearch A/S, where he was responsible for all aspects of pre-clinical and clinical drug development.
Peter holds a PhD in medicinal chemistry from the Royal Danish School of Pharmacy. He has also been a post doc with Yale University's department of organic chemistry.
Kenneth Harrison, Ph.D. | Senior Associate, Novo Ventures
Ken joined Novo Ventures in San Francisco, California in 2015. He was previously a Senior Market Planning Manager at Genentech, where he helped guide strategic decision making for the Ophthalmology and HER2 franchises. Prior to Genentech, Ken worked as a management consultant at L.E.K. Consulting and as the Entrepreneurship Program Manager at QB3/Mission Bay Capital, where he helped create new programs to launch and support life sciences companies in the Bay Area.
Ken studied cellular lipid storage and metabolism as an A.P. Giannini Foundation Fellow at the J. David Gladstone Institutes and earned a PhD in Pharmacology from Yale University.
About the Meet With... Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCI, NCATS, NINDS, Allegory Venture Partners, Clarus Ventures, Johnson & Johnson Innovation, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.
JLABS @ SSF
329 Oyster Point Blvd - 3rd Floor
South San Francisco, California